LUMIGAN SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

BIMATOPROST

Prieinama:

ALLERGAN INC

ATC kodas:

S01EE03

INN (Tarptautinis Pavadinimas):

BIMATOPROST

Dozė:

0.03%

Vaisto forma:

SOLUTION

Sudėtis:

BIMATOPROST 0.03%

Vartojimo būdas:

OPHTHALMIC

Vienetai pakuotėje:

3ML/5ML/7.5ML

Recepto tipas:

Prescription

Gydymo sritis:

PROSTAGLANDIN ANALOGS

Produkto santrauka:

Active ingredient group (AIG) number: 0147303001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2023-11-17

Prekės savybės

PRODUCT MONOGRAPH
Pr
LUMIGAN
®
Bimatoprost
Ophthalmic Solution 0.03% w/v
Elevated Intraocular Pressure Therapy
Prostamide Analogue
Allergan Inc.
Markham, ON
L6G 0B5
Date of Revision:
November 26, 2018
Submission Control No: 219412
_ _
_ _
_Page 2 of 29_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
3
DOSAGE AND ADMINISTRATION
........................................................................................
4
OVERDOSAGE
......................................................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................................
5
ADVERSE REACTIONS
..........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
10
STORAGE AND STABILITY
..................................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 12
PART II: SCIENTIFIC INFORMATION
.......................................................................................
13
PHARMACEUTICAL INFORMATION
...................................................................................
13
CLINICAL TRIALS
................................................................................................